Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma

作     者：Patrick Arbuthnot Liam Jed Thompson 

作者机构：Antiviral GeneTherapy Research UnitDepartment of Molecular Medicine andHaematologyUniversity of the Witwatersrand Medical SchoolPrivate Bag 3WITS 2050South Africa 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2008年第14卷第11期

页      面：1670-1681页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：The Cancer Association of South Africa,theSixth Research Framework Programme of the European UnionProject RIGHT,LSHB-CT-2004-005276 South African NationalResearch Foundation and Poliomyelitis Research Foundationsupport research 

主　　题：RNA interference Hepatocellular carcinoma Hepatitis B virus Hepatitis C virus Molecular pathogenesis Delivery vectors 

摘      要：Primary liver cancer is the fifth most common malignan- cy in the world and is a leading cause of cancer-related *** treatment for hepatocellular carcino- ma(HCC),the commonest primary liver cancer,is rarely curative and there is a need to develop therapy that is more *** and powerful gene silencing that can be achieved by activating RNA interference(RNAi) has generated enthusiasm for exploiting this pathway for HCC *** studies have been carried out with the aim of silencing HCC-related cellular oncogenes or the hepatocarcinogenic hepatitis B virus(HBV)and hepatitis C virus(HCV).Proof of principle studies have demonstrated promising results,and an early clinical trial assessing RNAi-based HBV therapy is currently in *** the data augur well,there are several significant hurdles that need to be overcome before the goal of RNAi-based therapy for HCC is ***- larly important are the efficient and safe delivery of RNAi effecters to target malignant tissue and the limitation of unintended harmful non-specific effects.